ES2262626T3 - Inhibidores de farnesil proteina transferasa para tratar cancer de mama. - Google Patents
Inhibidores de farnesil proteina transferasa para tratar cancer de mama.Info
- Publication number
- ES2262626T3 ES2262626T3 ES01905717T ES01905717T ES2262626T3 ES 2262626 T3 ES2262626 T3 ES 2262626T3 ES 01905717 T ES01905717 T ES 01905717T ES 01905717 T ES01905717 T ES 01905717T ES 2262626 T3 ES2262626 T3 ES 2262626T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- breast cancer
- inhibitor
- pharmaceutical composition
- farnesyl protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 18
- 239000003112 inhibitor Substances 0.000 title claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 title description 11
- 102000004169 proteins and genes Human genes 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 title description 3
- 229950008696 farnesil Drugs 0.000 title description 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- PLHJCIYEEKOWNM-UHFFFAOYSA-N 6-[amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical group CN1C=NC=C1C(N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 102000004357 Transferases Human genes 0.000 claims description 10
- 108090000992 Transferases Proteins 0.000 claims description 10
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000012268 protein inhibitor Substances 0.000 claims 1
- 229940121649 protein inhibitor Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 108010014186 ras Proteins Proteins 0.000 description 10
- 102000016914 ras Proteins Human genes 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 108700020796 Oncogene Proteins 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 102000043276 Oncogene Human genes 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 108700042226 ras Genes Proteins 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 4
- 102100029974 GTPase HRas Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- -1 imidazolyl-5-yl Chemical group 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000686227 Homo sapiens Ras-related protein R-Ras2 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 2
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 2
- 102100025003 Ras-related protein R-Ras2 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- POYSUXIHCXBJPN-UHFFFAOYSA-N 3-Methyl-quinolin-2-ol Chemical class C1=CC=C2NC(=O)C(C)=CC2=C1 POYSUXIHCXBJPN-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 206010012373 Depressed level of consciousness Diseases 0.000 description 1
- 102100022874 Dexamethasone-induced Ras-related protein 1 Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000620808 Homo sapiens Dexamethasone-induced Ras-related protein 1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000034918 positive regulation of cell growth Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00200373 | 2000-02-04 | ||
| EP00200373 | 2000-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2262626T3 true ES2262626T3 (es) | 2006-12-01 |
Family
ID=8170976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01905717T Expired - Lifetime ES2262626T3 (es) | 2000-02-04 | 2001-02-01 | Inhibidores de farnesil proteina transferasa para tratar cancer de mama. |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20030027839A1 (https=) |
| EP (1) | EP1255537B1 (https=) |
| JP (1) | JP5491681B2 (https=) |
| AT (1) | ATE323474T1 (https=) |
| AU (1) | AU2001233726A1 (https=) |
| CA (1) | CA2396865C (https=) |
| CY (1) | CY1105477T1 (https=) |
| DE (1) | DE60118889T2 (https=) |
| DK (1) | DK1255537T3 (https=) |
| ES (1) | ES2262626T3 (https=) |
| PT (1) | PT1255537E (https=) |
| SI (1) | SI1255537T1 (https=) |
| WO (1) | WO2001056552A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| DE60230017D1 (de) * | 2001-02-15 | 2009-01-08 | Janssen Pharmaceutica Nv | Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen |
| WO2003047697A2 (en) * | 2001-11-30 | 2003-06-12 | Schering Corporation | Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer |
| US7102251B2 (en) * | 2003-08-22 | 2006-09-05 | Distributed Power, Inc. | Bi-directional multi-port inverter with high frequency link transformer |
| JP2007510661A (ja) * | 2003-11-06 | 2007-04-26 | シェーリング コーポレイション | 乳癌の治療のための、ファルネシルトランスフェラーゼインヒビターと抗ホルモン剤との組合せ |
| RU2006124843A (ru) | 2003-12-12 | 2008-01-20 | Уайт (Us) | Хинолины, пригодные для лечения сердечно-сосудистого заболевания |
| US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
| US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| CA2559282A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| WO2005089518A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Uch-l1 expression and cancer therapy |
| CA2559285A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
| US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
| EP1968591A4 (en) | 2005-12-23 | 2010-02-17 | Link Medicine Corp | TREATMENT OF SYNUCLEINOPATHIES |
| WO2009151683A2 (en) * | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| JP2012508768A (ja) * | 2008-11-13 | 2012-04-12 | リンク・メディスン・コーポレーション | アザキノリノン誘導体及びその使用 |
| EP2288195B1 (en) * | 2009-08-20 | 2019-10-23 | Samsung Electronics Co., Ltd. | Method and apparatus for operating a base station in a wireless communication system |
| CA2888485C (en) | 2012-10-16 | 2021-01-26 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of ror.gamma.t |
| MY189505A (en) | 2012-10-16 | 2022-02-16 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of roryt |
| ES2619610T3 (es) | 2012-10-16 | 2017-06-26 | Janssen Pharmaceutica Nv | Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| BR112016008215A2 (pt) | 2013-10-15 | 2017-09-26 | Janssen Pharmaceutica Nv | moduladores de quinolinila ligados por alquila de roryt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| ES2742843T3 (es) | 2013-10-15 | 2020-02-17 | Janssen Pharmaceutica Nv | Moduladores de quinolinilo de ROR(gamma)t |
| HUE044698T2 (hu) | 2015-08-17 | 2019-11-28 | Kura Oncology Inc | Kezelési módszer rákos páciensek kezelésére farnezil-transzferáz inhibitorokkal |
| JP2019534290A (ja) | 2016-11-03 | 2019-11-28 | クラ オンコロジー， インコーポレイテッド | 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69620445T2 (de) * | 1995-12-08 | 2002-12-12 | Janssen Pharmaceutica N.V., Beerse | (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren |
| US5874442A (en) * | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| US5994364A (en) * | 1996-09-13 | 1999-11-30 | Schering Corporation | Tricyclic antitumor farnesyl protein transferase inhibitors |
| TW591030B (en) * | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
| RU2205831C2 (ru) * | 1997-04-25 | 2003-06-10 | Янссен Фармацевтика Н.В. | Хиназолиноны, ингибирующие фарнезилтрансферазу |
| US5925639A (en) * | 1997-06-17 | 1999-07-20 | Schering Corporation | Keto amide derivatives useful as farnesyl protein transferase inhibitors |
| US5852034A (en) * | 1997-06-17 | 1998-12-22 | Schering Corporation | Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors |
| US6096757A (en) * | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
| WO2000001701A1 (en) * | 1998-07-02 | 2000-01-13 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| PL193464B1 (pl) * | 1998-07-06 | 2007-02-28 | Janssen Pharmaceutica Nv | Zastosowanie inhibitora białkowej transferazy farnezylowej |
| DE69923849T2 (de) * | 1998-08-27 | 2006-01-12 | Pfizer Products Inc., Groton | Quinolin-2-on-derivate verwendbar als antikrebsmittel |
| DK1140935T3 (da) * | 1998-12-23 | 2003-09-01 | Janssen Pharmaceutica Nv | 1,2-anellerede quinolinderivater |
| AU2292801A (en) * | 1999-12-22 | 2001-07-03 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Compositions and methods for treatment of breast cancer |
| ATE375794T1 (de) * | 2000-02-24 | 2007-11-15 | Janssen Pharmaceutica Nv | Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs |
| WO2001064252A2 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| US20020022633A1 (en) * | 2000-06-30 | 2002-02-21 | Williams Theresa M. | Inhibitors of prenyl-protein transferase |
-
2001
- 2001-02-01 SI SI200130572T patent/SI1255537T1/sl unknown
- 2001-02-01 AU AU2001233726A patent/AU2001233726A1/en not_active Abandoned
- 2001-02-01 ES ES01905717T patent/ES2262626T3/es not_active Expired - Lifetime
- 2001-02-01 CA CA002396865A patent/CA2396865C/en not_active Expired - Lifetime
- 2001-02-01 WO PCT/EP2001/001032 patent/WO2001056552A2/en not_active Ceased
- 2001-02-01 DK DK01905717T patent/DK1255537T3/da active
- 2001-02-01 AT AT01905717T patent/ATE323474T1/de active
- 2001-02-01 PT PT01905717T patent/PT1255537E/pt unknown
- 2001-02-01 US US10/203,083 patent/US20030027839A1/en not_active Abandoned
- 2001-02-01 DE DE60118889T patent/DE60118889T2/de not_active Expired - Lifetime
- 2001-02-01 JP JP2001556244A patent/JP5491681B2/ja not_active Expired - Lifetime
- 2001-02-01 EP EP01905717A patent/EP1255537B1/en not_active Expired - Lifetime
-
2004
- 2004-04-06 US US10/818,767 patent/US20040192726A1/en not_active Abandoned
-
2006
- 2006-07-18 CY CY20061100995T patent/CY1105477T1/el unknown
-
2008
- 2008-09-16 US US12/211,705 patent/US20090018164A1/en not_active Abandoned
-
2011
- 2011-01-06 US US12/985,579 patent/US20110098318A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040192726A1 (en) | 2004-09-30 |
| WO2001056552A3 (en) | 2002-04-25 |
| DK1255537T3 (da) | 2006-08-21 |
| WO2001056552A2 (en) | 2001-08-09 |
| US20110098318A1 (en) | 2011-04-28 |
| US20030027839A1 (en) | 2003-02-06 |
| DE60118889T2 (de) | 2006-11-30 |
| AU2001233726A1 (en) | 2001-08-14 |
| DE60118889D1 (de) | 2006-05-24 |
| JP5491681B2 (ja) | 2014-05-14 |
| CA2396865C (en) | 2009-04-14 |
| CY1105477T1 (el) | 2010-04-28 |
| US20090018164A1 (en) | 2009-01-15 |
| JP2003521509A (ja) | 2003-07-15 |
| CA2396865A1 (en) | 2001-08-09 |
| EP1255537B1 (en) | 2006-04-19 |
| PT1255537E (pt) | 2006-09-29 |
| SI1255537T1 (sl) | 2006-10-31 |
| ATE323474T1 (de) | 2006-05-15 |
| EP1255537A2 (en) | 2002-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2262626T3 (es) | Inhibidores de farnesil proteina transferasa para tratar cancer de mama. | |
| EP2786754B1 (en) | Combination therapy with a mitotic inhibitor | |
| EP1002556A2 (en) | Use of MMP inhibitors | |
| ES2318000T3 (es) | Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos. | |
| EP2263694A1 (en) | Antitumor agent comprising the histone deacetylase inhibitor FK228 and a topoisomerase II inhibitor | |
| RU2401662C2 (ru) | Фармацевтические композиции и способы лечения рака и его метастазов | |
| WO1994016687A1 (en) | Use of creatine or analogs for the manufacture of a medicament for inhibiting tumor growth | |
| EP0774255B1 (en) | Use of ursolic acid for the manufacture of a medicament for suppressing metastasis | |
| PT2146721E (pt) | Métodos de utilização de antagonistas da vasopressina com agentes quimioterapeuticos de antraciclina para reduzir a cardiotoxicidade e/ou melhorar a sobrevivência | |
| CN101808636B (zh) | 黑色素瘤的治疗 | |
| CN116077631A (zh) | 涉及粘液素的疾病治疗 | |
| JP2010031043A (ja) | ガンの治療 | |
| ES2414861T3 (es) | Uso del FTS para el tratamiento de trastornos malignos | |
| KR19990082064A (ko) | 피페라진 옥시란 유도체를 사용하여 신생 세포의 사멸을유도하는 방법 | |
| KR102002581B1 (ko) | 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물 | |
| EP3829623A1 (en) | Methods for reducing abnormal scar formation | |
| EP3010508B1 (en) | Combination of ro5503781, capecitabine and oxaliplatin for cancer therapy | |
| CN115869316A (zh) | 伊斯平斯在制备联合抗乳腺癌药物方面的用途 | |
| EP3010513B1 (en) | Combination of ro5503781 and capecitabine for cancer therapy | |
| JP2003509383A (ja) | 化学療法を強化し、充実性腫瘍を治療する方法 | |
| CN120091822A (zh) | 用于肿瘤血管阻断的药物组合物 | |
| CA2120234A1 (en) | 2-aminopropan-1,3-diol chemotherapeutic agents | |
| KR20100131457A (ko) | 시티딘 유도체 및 카르보플라틴을 함유하는 항종양제 | |
| HK1229695A1 (en) | Novel methods for treating cancer | |
| HK1128234B (en) | Combination comprising combretastatin and anticancer agents |